BPC-157 Capsule Dosage: Published Study Data

No human dosing recommendation can be made regarding BPC-157 capsules dosage. That is the most important sentence on this page. Every dose listed below comes from published animal studies conducted in rats, mice, or dogs. Translating animal doses to human equivalents requires validated pharmacokinetic data that does not exist for this peptide. We present the research doses, explain how to read a capsule label, and describe why the gap between animal data and human application remains unbridged.

Why No Human Dose Can Be Recommended

Three conditions must be met before a responsible dosing recommendation can be made for any compound: completed human pharmacokinetic studies, dose-response data from controlled trials, and regulatory review of safety margins. BPC-157 has none of these. The 2022 pharmacokinetic study measured absorption in rats and dogs only. No human PK data exists for any route, oral or injectable. Without knowing how humans absorb, distribute, metabolize, and excrete BPC-157, any "recommended dose" is a guess.

Sources available online specifying human doses, namely 250-500 mcg two times a day, derive such data from animal studies by means of an allometric scaling formula. The allometric scaling formula was created for small molecules with verified absorption properties. Using the formula for 15-amino acid peptide with unknown oral bioavailability entails several inaccuracies and areas of uncertainty. So we do not promote this type of extrapolation.

Doses Used in Published Animal Studies

The table below presents information collected from peer-reviewed studies on dosage. Each dosage is reported in micrograms per kilogram of body weight (mcg/kg), which is the usual increment of dosage in preclinical research. The route of administration comprises the type of animal used in the research and its duration, as both these factors influence how we could apply the dosage to human beings in the future.

In the studies conducted orally, the most effective dose used is 10 mcg/kg body weight for rats. Some studies performed with doses as low as 0.01 mcg/kg (10 ng/kg) still showed measurable effects. In safety studies conducted in the PK study, doses up to 20 mg/kg have been tested with no signs of toxicity. This indicates that there is a 2,000-fold difference between the effective dose and that tested for toxicity so pointing to a large potential for an effective dose in rats. It is unknown whether this applies to other species.

How to Read a BPC-157 Capsule Label

Anyone researching BPC-157 capsules dosage needs to pay attention to several details while trying to understand what exactly the capsule label has to tell.

Micrograms per Capsule

The majority of capsule products indicate the quantity of the peptide in each capsule in micrograms (mcg). For example, Real Peptides offers capsules containing 500 mcg in each capsule which translates to being 0.5 mg in each capsule. This also means that there is a total of 50 mg of peptide in a bottle of 100 capsules of 500 mcg each. It is often not clear whether the label mentions the weight of only peptide or both peptide and its counter-ion (in form of salt) which is important.

Salt Form

BPC-157 is available as an acetate salt and arginate salt (Na-BPC). While the salt contributes to the total weight, it is not considered the active peptide sequence. A "500 mcg" capsule with arginate salt will have a different weight of active GEPPPGKPADDAGLV peptide than a "500 mcg" capsule with acetate salt unless the label states that it refers to the free peptide. Most of the labels do not specify this.

Capsule Count and Total Content

Find the total peptide content by taking the dose per capsule and multiplying it by the number of capsules taken. For instance, Real Peptides' dose is 500 mcg and they come in 100 capsules, equaling to a total peptide content of 50,000 mcg or 50 mg. The price for the bottle is $120 meaning the price per mg is $2.40. In terms of injections, taking the company's vial containing 10 mg of peptide for $43.20 gives a price per mg of $4.32. In this case, capsules are less expensive than injections; however, it remains unclear how the two methods compare in terms of bioavailability in humans.

Certificate of Analysis

A COA should show HPLC purity data, peptide content verification, and ideally endotoxin screening. Third-party testing from an independent lab is stronger evidence than in-house testing. If a capsule product has no COA, you cannot verify that it contains BPC-157 at the stated dose, or that it contains BPC-157 at all. Products without published COAs should be treated with caution regardless of price.

Why Allometric Scaling Falls Short

Allometric scaling uses body surface area ratios to convert animal doses to estimated human equivalent doses. The FDA provides a standard conversion table for this purpose. For rats to humans, the conversion factor is approximately 6.2 (divide the rat dose in mg/kg by 6.2 to estimate the human equivalent). Applying this to the common rat oral dose of 10 mcg/kg yields roughly 1.6 mcg/kg as an estimated human equivalent, or about 112 mcg for a 70 kg person.

The math seems rather simple. The issue is that it incorrectly presumes that all species have similar bioavailability, however this has yet to be established. It assumes that there will be a linear dose-response which has never been shown in humans. It also assumes that the use of an oral capsule will administer the peptide in the same way as when it is given to rats, which has never been verified under test conditions. Each one of these makes the assumption unreliable.